补肾壮骨胶囊治疗KOA的疗效观察及对MMP-1、TIMP-1、ADAMTS-4表达的影响
|
摘要
目的观察补肾壮骨胶囊治疗膝骨性关节炎的疗效,并探讨其作用机理及补肾壮骨胶囊对膝骨性关节炎软骨细胞ADAMTS-4、MMP-1、TIMP-1表达的影响。
方法实验研究将新西兰白兔40只分为A正常组、B模型组、C治疗组、D对照组,B, C, D三组按照Hulth造模方法造成兔膝骨性关节炎模型。C组给予补肾壮骨胶囊,D组给予壮骨关节丸。给药8周后行实验兔膝关节X光检查,动物处死后观察兔膝关节大体形态并测定关节软骨MMP-1、TIMP-1、ADAMTS-4阳性细胞数。临床研究应用补肾壮骨胶囊、壮骨关节丸治疗膝骨性关节炎患者各30例,对照观察临床总疗效。
结果动物实验研究显示模型组膝关节软骨有明显退行性改变,HE染色光镜观察及软骨中MMP-1、TIMP-1、和ADAMTS-4的表达显示,治疗组和模型组比较有显著差异(P<0.01),治疗组和对照组相关检测指标没有显著差异(P>0.05),临床研究显示应用补肾壮骨胶囊治疗膝骨性关节炎总有效率和对照组相比有明显差异(P<0.05)。
结论关节软骨中的MMP-1和ADAMTS-4是引起膝骨性关节炎的重要的酶,MMP-1和ADAMTS-4的过多表达可能是关节软骨退变的重要原因之一,补肾壮骨胶囊通过提高关节软骨TIMP-1的表达及抑制MMP-1和ADAMTS-4的表达保护软骨,改善膝关节功能。
Objective :To observe the efficacy of Bushenzhuanggu capsule(BSZGC) for treatment of knee osteoarthritis(KOA) and its mechanism.To observe effects on knee osteoarthritis chondrocytes ADAMTS-4, MMP-1, TIMP-1 expression.
Methods: In the experiment study ,40 New Zealand rabbits were randomly divided into 4 groups:Group A (the normal group),Group B (the model group),Group C(the treated group) and Group D(the control group).KOA models were created in Group B, C and D by Hulth’s operation methods. The rabbits in Group D were treated with Zhuangguguanjie pill (ZGGJP) and BSZGC was used in Group C. 8 weeks later, to make CR of the knee, Then to kill the rabbits and get the femoral condyle and measured MMP-1, TIMP-1, ADAMTS-4 positive cells. Clinical research applications BSZGC,ZGGJP treatment of KOA of the 30 patients in the control and the overall clinical efficacy observed symptoms and signs improve the situation.
Results : The experiment study showed the model group significantly articular cartilage degeneration, HE staining and light microscopy MMP-1, TIMP-1, and ADAMTS-4 expression showed that the treatment group and model group were significantly different(P <0.01), treatment group and control group of related indicators no significant differences detected (P> 0.05), Clinical studies have shown that application of BSZGC of KOA total efficiency and the control group were significantly different (P <0.05).
Conclusions :MMP-1 and ADAMTS-4 expression may be too much of articular cartilage degeneration is one of the important reasons, BSZGC articular cartilage by increasing the expression of TIMP-1 and inhibition of MMP-1 and ADAMTS-4 expression to effectively improve KOA in patients with clinical symptoms and restore knee function.
方法实验研究将新西兰白兔40只分为A正常组、B模型组、C治疗组、D对照组,B, C, D三组按照Hulth造模方法造成兔膝骨性关节炎模型。C组给予补肾壮骨胶囊,D组给予壮骨关节丸。给药8周后行实验兔膝关节X光检查,动物处死后观察兔膝关节大体形态并测定关节软骨MMP-1、TIMP-1、ADAMTS-4阳性细胞数。临床研究应用补肾壮骨胶囊、壮骨关节丸治疗膝骨性关节炎患者各30例,对照观察临床总疗效。
结果动物实验研究显示模型组膝关节软骨有明显退行性改变,HE染色光镜观察及软骨中MMP-1、TIMP-1、和ADAMTS-4的表达显示,治疗组和模型组比较有显著差异(P<0.01),治疗组和对照组相关检测指标没有显著差异(P>0.05),临床研究显示应用补肾壮骨胶囊治疗膝骨性关节炎总有效率和对照组相比有明显差异(P<0.05)。
结论关节软骨中的MMP-1和ADAMTS-4是引起膝骨性关节炎的重要的酶,MMP-1和ADAMTS-4的过多表达可能是关节软骨退变的重要原因之一,补肾壮骨胶囊通过提高关节软骨TIMP-1的表达及抑制MMP-1和ADAMTS-4的表达保护软骨,改善膝关节功能。
Objective :To observe the efficacy of Bushenzhuanggu capsule(BSZGC) for treatment of knee osteoarthritis(KOA) and its mechanism.To observe effects on knee osteoarthritis chondrocytes ADAMTS-4, MMP-1, TIMP-1 expression.
Methods: In the experiment study ,40 New Zealand rabbits were randomly divided into 4 groups:Group A (the normal group),Group B (the model group),Group C(the treated group) and Group D(the control group).KOA models were created in Group B, C and D by Hulth’s operation methods. The rabbits in Group D were treated with Zhuangguguanjie pill (ZGGJP) and BSZGC was used in Group C. 8 weeks later, to make CR of the knee, Then to kill the rabbits and get the femoral condyle and measured MMP-1, TIMP-1, ADAMTS-4 positive cells. Clinical research applications BSZGC,ZGGJP treatment of KOA of the 30 patients in the control and the overall clinical efficacy observed symptoms and signs improve the situation.
Results : The experiment study showed the model group significantly articular cartilage degeneration, HE staining and light microscopy MMP-1, TIMP-1, and ADAMTS-4 expression showed that the treatment group and model group were significantly different(P <0.01), treatment group and control group of related indicators no significant differences detected (P> 0.05), Clinical studies have shown that application of BSZGC of KOA total efficiency and the control group were significantly different (P <0.05).
Conclusions :MMP-1 and ADAMTS-4 expression may be too much of articular cartilage degeneration is one of the important reasons, BSZGC articular cartilage by increasing the expression of TIMP-1 and inhibition of MMP-1 and ADAMTS-4 expression to effectively improve KOA in patients with clinical symptoms and restore knee function.
引文
[1]吴孟超,吴在德.黄家驷外科学[M],北京:人民卫生出版社,2008,第7版:3025-3027.
[2]李超,曹永平,关振鹏.蛋白聚糖酶和骨关节炎[J].北京大学学报(医学版),2009;41(5):611-613.
[3]张世华,蔡余力,李刚,等.补肾壮骨胶囊治疗膝关节骨性关节炎临床研究[J].山东中医杂志,2006;25(12):818-819.
[4]翟吉良,翁习生,邱贵兴.骨关节炎动物模型的建立及选择[J].中国矫形外科杂志,2007;15(11):843-845.
[5] Mankin HJ,Dorfman H, Lippiello L, et al.Biochemical and metabolic abnormalities in articular cartilage from osteo arthritic human hips.Ⅱ.Correlation of morphology with biochemical and metabolic data.[ J] .Bone Joint Surg Am,1971;53(3):523-537.
[6]中华医学会骨科学分会7版.骨关节炎诊治指南(2007年版)诊断标准[J].中国临床医生杂志,2008;36(1):28-30.
[7]王亦璁.骨与关节损伤[M],北京:人民卫生出版社,2007,第4版:738.
[8] Fosang AJ,Rogerson FM,East CJ,et al.ADAMTS-5:The story so far[J].Eur Cell Mater,2008;15(1):11-26.
[9] Reddi AH.Aging, osteoarthritis and transforming g rowth factorbeta signaling in cartilage[J].Arthritis Res Ther,2006;8:101.
[10] Kim KS, Choi HM, Lee YA,et al.Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis[J].Rheumatol Int,2011;31(4):543-7.
[11] Koskinen A, Vuolteenaho K, Nieminen R, et al.Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients[J].Clin Exp Rheumatol,2011;29(1):57-64.
[12] Burrage PS,Mix KS,Brinckerhoff CE.Matrix metalloproteinases:role in arthritis[J].Front Biosei,2006,1l(1):529-543.
[13] Pelletier JP,Raynauld JP,Caron J,et a1.Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis[J].Ann Rheum Dis,2010;69(12):2095-101.
[14] Steven; AI., Wheeler CA, Tannenbaum SR, et al.Nitric oxide enhances aggrecan degradation by aggremnase in response to TNF-alpha but not IL- lbeta treatment,at a post-transcriptional level in bovine cartilage explants[J].Osteoarthritis Cartilage, 2008;16(4):489-497.
[15] Kamm JL, Nixon AJ, Witte TH.Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi[J].Equine Vet J,2010;42(8):693-9.
[16] Sandy JD,Flannery CR,Neame PJ,et a1.The structure of aggrecan fragments in human synovial fuid.Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu373-Ala374 bond of the interglobular domain[J].J Clin Invest,1992;89:1512-1516.
[17] Jefery A Miller,Liu RQ,Gary L Davis,et a1.A microplate assay specific for the enzyme aggrecanase [J].Analytical Biochemistry,2003;314:260-265.
[18] Sandy JD,Neame PJ,Boynton RE,et a1.Catabolism of aggrecan in cartilage explants.Identification of a major cleavage site within the interglobular domain[J].J Biol Chem,1991;266(14):8683~8685.
[19] Tortorella MD,Burn TC,Pratta MA,et al.Purification and cloning of aggrecanase-1:Amember of the ADAMTS family of proteins[J].Science,1999;284(5420):1664-1666.
[20] van Wurs JB, van Lent PI,van de Loo AA, et al.Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis[J] .Ann Rheum Dis,1999;58(6):350-356.
[21] Walfit AM, Liu RQ, Ijiri K, et al.Inhibition of ADAMTS-4 and ADAMTS-5 prevents aggrecan degradation in osteoarthritic cartilage[J] .J Biol Chem,2002; 277(25):22201-22208.
[22] Tortorella M, Pratta M, Liu R-Q, et al.The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage[J] .J Biol Chem ,2000; 275: 25791-5797.
[23]闫新峰,常晓天,张明,等. ADAMTS-4在多种软骨中的表达[J].中华外科杂志,2008;46(3):228-229.
[24] Majumdar MK, Askew R, Schelling S, et al.Double -knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis[J] .Arthritis Rheum,2007; 56(11):3670-3674.
[25] Cheung KS, Hashimoto K, Yamada N, et al.Expression of ADAMTS-4 by chondrocytes in the surface zone of human osteoarthritic cartilage is regulated by epigenetic DNA de-methylation [J] .Rheumatol Int,2009;29(5):525-34.
[26]赵佶.圣济总录精华本[M],北京:科学出版社,1998,第1版:41.
[27]王和鸣.中医伤科学[M],北京:中国中医药出版社,2002,第1版:325-326.
[28]齐立卿,王金榜,杜双庆.养元柔肝汤治疗膝骨关节炎183例疗效观察[J].河北医科大学中医院学报,2009;24(3):14-15.
[29]文昌义.补肾温阳法治疗早中期膝关节骨性关节炎[J].光明中医,2010;25(7):1213-1214.
[30]杨锦华.膝骨性关节炎用药规律及其研究思路[J].中医研究,2010 ;23(5):74-76.
[31]王和鸣,于丹丹,汤婷婷,等.龟鹿二仙胶汤及其拆方对关节软骨细胞增殖的作用[J] .中国中医骨伤杂志,2007;15(7):45-59.
[32]王静,李建平,张跃文,等.淫羊藿药理学研究进展[J] .中国药业,2009;18(8):60-61.
[33]李花.淫羊藿药理总用的研究现状及展望[J].现代医药卫生,2008;24(22):3413-3414.
[34]刘培建,苗明三,高渐联.熟地黄多糖对气血双虚小鼠全血细胞及血清粒-巨噬细胞集落刺激因子水平的影响[J].中国组织工程研究与临床康复,2008;12(38):7543—7546.
[35]辛晓明,冯蕾,王浩,等.杜仲的化学成分及药理活性研究进展[J].医学综述,2007;13(19):1507-1508.
[36]夏海燕,吴晓萍,王兴中.牛膝多糖的化学组成和药理作用概述[J].山西中医,2010;26(5):44-45.
[37]李昌崇,胡晓光,张维溪,等.哮喘幼年大鼠嗜酸细胞凋亡、fas mRNA和bcl-2 mRNA表达及牛膝多糖的影响.中华儿科杂志,2003;41(9):657.
[38]李颜,郭澄.威灵仙化学成分和药理作用研究进展[J].中国药房,2008;19(33):2626-2627.
[39] Chan SS,Cheng TY,Lin G.Relaxation effects of ligustilide and senkyunolide A, two main constituents of Ligusticum chuanxiong, in rat isolated aorta[J] . J of Ethnopharmacology,2007;111(3):677-80.
[40]康丽,颜晓燕,辛志伟.红花的药理作用研究进展[J].西南军医,2008;10(6):136-137.
[41]蔡余力,李刚,颜冰等.补肾壮骨胶囊治疗膝关节骨性关节炎的实验研究[J] .中医正骨,2006;18(10):1-4.
[1] Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis:paet II, osteoarthritis of the knee[J]. Arthritis Rheum,1995;38:1541-1546.
[2] Hall KD.Differential strength decline in patient with OA of the knee[J].Arthritis Care Res,l993;6:89-98.
[3]倪国新,吴宗耀,成海平,等.关节制动对韧带的影响[J].国外医学一物理医学与康复分册,1997;1:6-9.
[4]郭建刚,冯坤,赵然,等.壮骨活血汤对骨性关节炎软骨退变防治作用的生化研究[J].中国骨伤,1999;12(5):19-21.
[5]黄枫,唐勇,郑晓辉,等.补肾强膝方对绝经后妇女膝骨性关节炎的影响[J].中医正骨,2002;14(4):12-14.
[6]苏小平.活血消积法治疗膝关节骨性关节炎105例临床研究[J].中国中医骨伤科杂志,2003;11(1):40-41.
[7]齐立卿,王金榜,杜双庆.养元柔肝汤治疗膝骨关节炎183例疗效观察[J].河北中医药学报,2009;24(3):14-15.
[8]赵志刚,王延青,黄本平.活血通痹汤治疗膝关节骨性关节炎128例疗效观察[J].山西中医,2010;26(3):23.
[9]葛继荣,王和鸣,杨连梓,等.复方杜仲健骨颗粒治疗膝关节骨性关节炎一期临床试验总结[J].中国中医骨伤科杂志,2002;10(5):19-23.
[10]谢晓馄.膝关节骨关节病常用治疗方法[J].中医正骨,2000;12(7):51-52.
[11]陈广祯,李心沁,梁安民,等.从瘀血痰湿论治膝关节骨关节炎58例[J].山东中医药大学学报,1998;22(1): 30-31.
[12]董福慧.奇正消痛贴膏治关节炎的临床疗效观察[J].继续医学教育,2005;19(7):77-81.
[13]唐祯.通痹活血膏治疗四肢骨性关节炎96例[J].中医药信息,2001;3:41.
[14]魏会东.乌鸡膏治疗膝关节骨性关节炎260例[J].中国民间疗法,2000;6(8):28.
[15]林燕云,林木南,李西海,等.中药熏洗治疗膝骨性关节炎的临床研究[J].福建中医药,2010;41(1):22-23.
[16]任彬,杨敏.针刺为主治疗膝骨性关节炎152例[J].中国针灸,2002;12(22):825.
[17]李岩松.针刺推拿治疗膝骨性关节96例临床观察[J].中国医药导报,2009;6(19):128-129.
[18]裘敏蕾,戴琪萍,车涛.电针膝眼穴治疗膝骨性关节炎的临床研究[J].中医正骨,2006;18(3):15.
[19]解培勋,彭易雨,景绘涛.火针膝眼穴为主治疗膝关节骨性关节炎120例疗效观察[J].河北中医药学报,2006;21(4):25.
[20]秦谊,李峰,刘清国等.针刀松解法治疗膝骨性关节炎的机理[J].中国康复理论与实践, 2010;16(4):397-398.
[21]杨旭辉,徐东明,孙杰,等.小针刀治疗膝关节骨性关节炎102例报告[J].针灸临床杂志,2002;18(9):37.
[22]柳百智.针刀治疗膝关节骨性关节炎126例[J].中国临床医生,2003;31(10):46-47.
[23]程宏毅,党建军,李强.湿热敷方配合西药及功能锻炼治疗膝骨性关节炎60例[J].陕西中医,2010;31(9):1177-1178.
[24]张保申.中药内外合治配合手法治疗膝关节骨性关节炎164例疗效观察[J].河北中医,2009;31(4):512-513.
[25]左可斌,任学通,李元贞.中药内服外洗治疗膝骨性关节炎108例[J].甘肃中医学院学报,2008;25(1):22-23.
[26]张密香,左艳,董博.针刺配合中药热敷治疗膝骨性关节炎45例[J].现代中医药,2006;26(3):40.
[27]娄海荣.骨性关节炎研究最新进展(三)[J].现代医院,2008;18(9):8-11.
[28]张志平,张玉生,李丕显.膝关节骨性关节炎的综台疗法[J].中国骨伤,1997;10(3):30.
[29]陆庄憔,谭乾,宋立坚,等.关节镜冲洗治疗膝关节骨性关节炎[J].中华骨科杂志,1990;10(4):281-283.
[30]马远征,鞠清涛.关节镜冲洗和强地松龙注射治疗膝关节骨性关节炎165例[J].人民军医,1991;7:43.
[31]姜杉,敖邦华,虞至忠,等.镜下清理术治疗膝关节骨性关节炎的体会[J].医学理论与实践,1994;7(1):33-34.
[32]张同仁,陈瑞光,陈鸿辉,等.关节镜清理术治疗膝关节骨性关节炎[J].中国内镜杂志,1999;5 (2):25-27.
[33]吕厚山.现代人工关节外科学[M].北京,人民卫生出版社,2006,第1版:34.
[34] S.Terry Canale主编,卢世璧主译.坎贝尔骨科手术学[M].济南,山东科技出版社,2000,第9版:407.
[35]唐涛,王安庆,刘克敏,等.保留髌骨全膝人工关节置术换治疗膝骨关节炎[J].中国康复理论与实践,2009;年15(6):514-516.
[36]李澎,李学良,吕萍.人工全膝关节表面置换治疗骨性关节炎59例[J].中国组织工程研究与临床康复,2009;13(4):747-751.
[37] Kafienah W,Mistry S,Dickinson SC,et a1.Three-dimensional cartilage tissue engineering using adult stem cells from Osteoarthristis patients[J].Arthrilis Rheum, 2007;56(1):177-187.
[2]李超,曹永平,关振鹏.蛋白聚糖酶和骨关节炎[J].北京大学学报(医学版),2009;41(5):611-613.
[3]张世华,蔡余力,李刚,等.补肾壮骨胶囊治疗膝关节骨性关节炎临床研究[J].山东中医杂志,2006;25(12):818-819.
[4]翟吉良,翁习生,邱贵兴.骨关节炎动物模型的建立及选择[J].中国矫形外科杂志,2007;15(11):843-845.
[5] Mankin HJ,Dorfman H, Lippiello L, et al.Biochemical and metabolic abnormalities in articular cartilage from osteo arthritic human hips.Ⅱ.Correlation of morphology with biochemical and metabolic data.[ J] .Bone Joint Surg Am,1971;53(3):523-537.
[6]中华医学会骨科学分会7版.骨关节炎诊治指南(2007年版)诊断标准[J].中国临床医生杂志,2008;36(1):28-30.
[7]王亦璁.骨与关节损伤[M],北京:人民卫生出版社,2007,第4版:738.
[8] Fosang AJ,Rogerson FM,East CJ,et al.ADAMTS-5:The story so far[J].Eur Cell Mater,2008;15(1):11-26.
[9] Reddi AH.Aging, osteoarthritis and transforming g rowth factorbeta signaling in cartilage[J].Arthritis Res Ther,2006;8:101.
[10] Kim KS, Choi HM, Lee YA,et al.Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis[J].Rheumatol Int,2011;31(4):543-7.
[11] Koskinen A, Vuolteenaho K, Nieminen R, et al.Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients[J].Clin Exp Rheumatol,2011;29(1):57-64.
[12] Burrage PS,Mix KS,Brinckerhoff CE.Matrix metalloproteinases:role in arthritis[J].Front Biosei,2006,1l(1):529-543.
[13] Pelletier JP,Raynauld JP,Caron J,et a1.Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis[J].Ann Rheum Dis,2010;69(12):2095-101.
[14] Steven; AI., Wheeler CA, Tannenbaum SR, et al.Nitric oxide enhances aggrecan degradation by aggremnase in response to TNF-alpha but not IL- lbeta treatment,at a post-transcriptional level in bovine cartilage explants[J].Osteoarthritis Cartilage, 2008;16(4):489-497.
[15] Kamm JL, Nixon AJ, Witte TH.Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi[J].Equine Vet J,2010;42(8):693-9.
[16] Sandy JD,Flannery CR,Neame PJ,et a1.The structure of aggrecan fragments in human synovial fuid.Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu373-Ala374 bond of the interglobular domain[J].J Clin Invest,1992;89:1512-1516.
[17] Jefery A Miller,Liu RQ,Gary L Davis,et a1.A microplate assay specific for the enzyme aggrecanase [J].Analytical Biochemistry,2003;314:260-265.
[18] Sandy JD,Neame PJ,Boynton RE,et a1.Catabolism of aggrecan in cartilage explants.Identification of a major cleavage site within the interglobular domain[J].J Biol Chem,1991;266(14):8683~8685.
[19] Tortorella MD,Burn TC,Pratta MA,et al.Purification and cloning of aggrecanase-1:Amember of the ADAMTS family of proteins[J].Science,1999;284(5420):1664-1666.
[20] van Wurs JB, van Lent PI,van de Loo AA, et al.Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis[J] .Ann Rheum Dis,1999;58(6):350-356.
[21] Walfit AM, Liu RQ, Ijiri K, et al.Inhibition of ADAMTS-4 and ADAMTS-5 prevents aggrecan degradation in osteoarthritic cartilage[J] .J Biol Chem,2002; 277(25):22201-22208.
[22] Tortorella M, Pratta M, Liu R-Q, et al.The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage[J] .J Biol Chem ,2000; 275: 25791-5797.
[23]闫新峰,常晓天,张明,等. ADAMTS-4在多种软骨中的表达[J].中华外科杂志,2008;46(3):228-229.
[24] Majumdar MK, Askew R, Schelling S, et al.Double -knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis[J] .Arthritis Rheum,2007; 56(11):3670-3674.
[25] Cheung KS, Hashimoto K, Yamada N, et al.Expression of ADAMTS-4 by chondrocytes in the surface zone of human osteoarthritic cartilage is regulated by epigenetic DNA de-methylation [J] .Rheumatol Int,2009;29(5):525-34.
[26]赵佶.圣济总录精华本[M],北京:科学出版社,1998,第1版:41.
[27]王和鸣.中医伤科学[M],北京:中国中医药出版社,2002,第1版:325-326.
[28]齐立卿,王金榜,杜双庆.养元柔肝汤治疗膝骨关节炎183例疗效观察[J].河北医科大学中医院学报,2009;24(3):14-15.
[29]文昌义.补肾温阳法治疗早中期膝关节骨性关节炎[J].光明中医,2010;25(7):1213-1214.
[30]杨锦华.膝骨性关节炎用药规律及其研究思路[J].中医研究,2010 ;23(5):74-76.
[31]王和鸣,于丹丹,汤婷婷,等.龟鹿二仙胶汤及其拆方对关节软骨细胞增殖的作用[J] .中国中医骨伤杂志,2007;15(7):45-59.
[32]王静,李建平,张跃文,等.淫羊藿药理学研究进展[J] .中国药业,2009;18(8):60-61.
[33]李花.淫羊藿药理总用的研究现状及展望[J].现代医药卫生,2008;24(22):3413-3414.
[34]刘培建,苗明三,高渐联.熟地黄多糖对气血双虚小鼠全血细胞及血清粒-巨噬细胞集落刺激因子水平的影响[J].中国组织工程研究与临床康复,2008;12(38):7543—7546.
[35]辛晓明,冯蕾,王浩,等.杜仲的化学成分及药理活性研究进展[J].医学综述,2007;13(19):1507-1508.
[36]夏海燕,吴晓萍,王兴中.牛膝多糖的化学组成和药理作用概述[J].山西中医,2010;26(5):44-45.
[37]李昌崇,胡晓光,张维溪,等.哮喘幼年大鼠嗜酸细胞凋亡、fas mRNA和bcl-2 mRNA表达及牛膝多糖的影响.中华儿科杂志,2003;41(9):657.
[38]李颜,郭澄.威灵仙化学成分和药理作用研究进展[J].中国药房,2008;19(33):2626-2627.
[39] Chan SS,Cheng TY,Lin G.Relaxation effects of ligustilide and senkyunolide A, two main constituents of Ligusticum chuanxiong, in rat isolated aorta[J] . J of Ethnopharmacology,2007;111(3):677-80.
[40]康丽,颜晓燕,辛志伟.红花的药理作用研究进展[J].西南军医,2008;10(6):136-137.
[41]蔡余力,李刚,颜冰等.补肾壮骨胶囊治疗膝关节骨性关节炎的实验研究[J] .中医正骨,2006;18(10):1-4.
[1] Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis:paet II, osteoarthritis of the knee[J]. Arthritis Rheum,1995;38:1541-1546.
[2] Hall KD.Differential strength decline in patient with OA of the knee[J].Arthritis Care Res,l993;6:89-98.
[3]倪国新,吴宗耀,成海平,等.关节制动对韧带的影响[J].国外医学一物理医学与康复分册,1997;1:6-9.
[4]郭建刚,冯坤,赵然,等.壮骨活血汤对骨性关节炎软骨退变防治作用的生化研究[J].中国骨伤,1999;12(5):19-21.
[5]黄枫,唐勇,郑晓辉,等.补肾强膝方对绝经后妇女膝骨性关节炎的影响[J].中医正骨,2002;14(4):12-14.
[6]苏小平.活血消积法治疗膝关节骨性关节炎105例临床研究[J].中国中医骨伤科杂志,2003;11(1):40-41.
[7]齐立卿,王金榜,杜双庆.养元柔肝汤治疗膝骨关节炎183例疗效观察[J].河北中医药学报,2009;24(3):14-15.
[8]赵志刚,王延青,黄本平.活血通痹汤治疗膝关节骨性关节炎128例疗效观察[J].山西中医,2010;26(3):23.
[9]葛继荣,王和鸣,杨连梓,等.复方杜仲健骨颗粒治疗膝关节骨性关节炎一期临床试验总结[J].中国中医骨伤科杂志,2002;10(5):19-23.
[10]谢晓馄.膝关节骨关节病常用治疗方法[J].中医正骨,2000;12(7):51-52.
[11]陈广祯,李心沁,梁安民,等.从瘀血痰湿论治膝关节骨关节炎58例[J].山东中医药大学学报,1998;22(1): 30-31.
[12]董福慧.奇正消痛贴膏治关节炎的临床疗效观察[J].继续医学教育,2005;19(7):77-81.
[13]唐祯.通痹活血膏治疗四肢骨性关节炎96例[J].中医药信息,2001;3:41.
[14]魏会东.乌鸡膏治疗膝关节骨性关节炎260例[J].中国民间疗法,2000;6(8):28.
[15]林燕云,林木南,李西海,等.中药熏洗治疗膝骨性关节炎的临床研究[J].福建中医药,2010;41(1):22-23.
[16]任彬,杨敏.针刺为主治疗膝骨性关节炎152例[J].中国针灸,2002;12(22):825.
[17]李岩松.针刺推拿治疗膝骨性关节96例临床观察[J].中国医药导报,2009;6(19):128-129.
[18]裘敏蕾,戴琪萍,车涛.电针膝眼穴治疗膝骨性关节炎的临床研究[J].中医正骨,2006;18(3):15.
[19]解培勋,彭易雨,景绘涛.火针膝眼穴为主治疗膝关节骨性关节炎120例疗效观察[J].河北中医药学报,2006;21(4):25.
[20]秦谊,李峰,刘清国等.针刀松解法治疗膝骨性关节炎的机理[J].中国康复理论与实践, 2010;16(4):397-398.
[21]杨旭辉,徐东明,孙杰,等.小针刀治疗膝关节骨性关节炎102例报告[J].针灸临床杂志,2002;18(9):37.
[22]柳百智.针刀治疗膝关节骨性关节炎126例[J].中国临床医生,2003;31(10):46-47.
[23]程宏毅,党建军,李强.湿热敷方配合西药及功能锻炼治疗膝骨性关节炎60例[J].陕西中医,2010;31(9):1177-1178.
[24]张保申.中药内外合治配合手法治疗膝关节骨性关节炎164例疗效观察[J].河北中医,2009;31(4):512-513.
[25]左可斌,任学通,李元贞.中药内服外洗治疗膝骨性关节炎108例[J].甘肃中医学院学报,2008;25(1):22-23.
[26]张密香,左艳,董博.针刺配合中药热敷治疗膝骨性关节炎45例[J].现代中医药,2006;26(3):40.
[27]娄海荣.骨性关节炎研究最新进展(三)[J].现代医院,2008;18(9):8-11.
[28]张志平,张玉生,李丕显.膝关节骨性关节炎的综台疗法[J].中国骨伤,1997;10(3):30.
[29]陆庄憔,谭乾,宋立坚,等.关节镜冲洗治疗膝关节骨性关节炎[J].中华骨科杂志,1990;10(4):281-283.
[30]马远征,鞠清涛.关节镜冲洗和强地松龙注射治疗膝关节骨性关节炎165例[J].人民军医,1991;7:43.
[31]姜杉,敖邦华,虞至忠,等.镜下清理术治疗膝关节骨性关节炎的体会[J].医学理论与实践,1994;7(1):33-34.
[32]张同仁,陈瑞光,陈鸿辉,等.关节镜清理术治疗膝关节骨性关节炎[J].中国内镜杂志,1999;5 (2):25-27.
[33]吕厚山.现代人工关节外科学[M].北京,人民卫生出版社,2006,第1版:34.
[34] S.Terry Canale主编,卢世璧主译.坎贝尔骨科手术学[M].济南,山东科技出版社,2000,第9版:407.
[35]唐涛,王安庆,刘克敏,等.保留髌骨全膝人工关节置术换治疗膝骨关节炎[J].中国康复理论与实践,2009;年15(6):514-516.
[36]李澎,李学良,吕萍.人工全膝关节表面置换治疗骨性关节炎59例[J].中国组织工程研究与临床康复,2009;13(4):747-751.
[37] Kafienah W,Mistry S,Dickinson SC,et a1.Three-dimensional cartilage tissue engineering using adult stem cells from Osteoarthristis patients[J].Arthrilis Rheum, 2007;56(1):177-187.